CORRECTION Open Access

Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & **EVOLVE-2**)



Stephen D. Silberstein^{1*}, Virginia L. Stauffer², Katie A. Day², Sarah Lipsius³ and Maria-Carmen Wilson⁴

Correction to: J Headache Pain https://doi.org/10.1186/s10194-019-1024-x

After publication of our article [1] we were notified that the data presented in the upper row of Fig. 7 was inadvertently the least square mean change from baseline (standard error) at Month 6 rather than the overall average of Month 3 and Month 6. The figure legend and discussion of the data in the text were and are correct. The error was only in the upper row of Fig. 7. The legend for Fig. 7 did not require revision.

¹ Jefferson Headache Center, Thomas Jefferson University, Philadelphia, PA, USA. ²Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana, USA. ³Syneos Health, Raleigh, NC, USA. ⁴Ochsner Health System, Covington, LA, USA.

Published online: 27 December 2019

Reference

Silberstein et al (2019) Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2). J Headache Pain 20:75. https://doi. org/10.1186/s10194-019-1024-x

Full list of author information is available at the end of the article



^{*} Correspondence: stephen.silberstein@jefferson.edu The original article can be found online at https://doi.org/10.1186/s10194-019-1024-x

¹Jefferson Headache Center, Thomas Jefferson University, Philadelphia, PA,




Fig. 7 The overall least-squares (LS) mean change in Migraine Disability Assessment (MIDAS) total Score for the average of Months 3 and 6 is shown for patients with LFEM and HFEM receiving placebo, 120-mg, or 240-mg of galcanezumab in the upper row. The LS mean changes in MIDAS total score at Months 3 and 6 for patients receiving these treatments is shown in the bottom row for patients with LFEM and with HFEM. *** $p \le .001$, ** $p \le .001$, ** $p \le .05$ vs placebo